# MED Project Brief v0.1

Date: 2026-06-17

## Short Definition

MED is a Kyoto-rooted medical professionals research vertical and project ticker. It is designed to connect busy MDs, PhDs, graduate students, university offices, corporate research institutes, pharmaceutical evidence teams, AI agents, and selected operators around high-value medical-science translation.

The first MED thesis is simple: Japan already has exceptional medical science, but the connective tissue between iPS research, regenerative dentistry, AI-assisted drug evidence, verified professional identity, and patent routing can be much stronger.

## Founder Context

- The founder is Kyoto University physics-trained and scientifically broad.
- The founder has access to a Dean's Club style alumni network with senior executives.
- The founder wants MED to connect Kyoto and Tokyo medical-science networks without overstating any formal institutional endorsement.
- The founder has a personal motivation around tooth regeneration, which should be handled as a serious translational research question rather than as a treatment promise.
- PAT is the sibling vertical for patenting, proof records, and lawyer-supervised IP routing.

## Scientific Anchors

- iPS cells and regenerative medicine.
- Regenerative dentistry and oral-tissue repair.
- AI-assisted literature, drug-data, trial, and evidence review.
- Clinical and real-world evidence workflows.
- Verified professional identity and contribution records.
- Patent disclosure discipline through PAT.

## Official Source Anchors

These sources are public anchors only. MED does not imply endorsement by these institutions.

- Kyoto University CiRA: https://www.cira.kyoto-u.ac.jp/e/
- Kyoto University Graduate School of Medicine and Faculty of Medicine: https://www.med.kyoto-u.ac.jp/en/
- University of Tokyo Graduate School of Medicine and Faculty of Medicine: https://www.m.u-tokyo.ac.jp/english/index.html
- PMDA electronic study data review page: https://www.pmda.go.jp/english/review-services/reviews/0002.html

## Project Rooms

1. `IPS-01` iPS translation desk
   - Question: where can AI reduce translation friction without creating unsafe clinical claims?
   - Output: watchlist by indication, cell type, safety bottleneck, manufacturing question, and reviewer.

2. `DENT-02` tooth regeneration bridge
   - Question: who can connect oral biology, stem cells, biomaterials, dental schools, and clinical ethics?
   - Output: partner map and first problem packets.

3. `DRUG-03` AI drug-data room
   - Question: where can agents increase speed in literature, evidence, and regulatory-data review?
   - Output: reviewer-approved AI workflow and contradiction log.

4. `ID-04` verified professional graph
   - Question: how do we verify expertise and credit while protecting privacy?
   - Output: TempleMirror-style consent-first identity policy.

5. `PAT-05` PAT disclosure route
   - Question: what is invention-worthy, who owns it, and how should it be protected?
   - Output: invention note, prior-art map, proof record, and counsel review packet.

6. `LAB-06` corporate and university pilot desk
   - Question: what pilots are concrete enough for corporate labs and university offices?
   - Output: pilot criteria, confidentiality boundary, publication policy, and review cadence.

## First Build Queue

- Regenerative dentistry map.
- iPS translation watchlist.
- AI evidence assistant.
- Dean's Club invitation packet.
- TempleMirror identity and consent policy.
- PAT invention-disclosure template for MED.

## Guardrails

- No clinical advice.
- No patient recruitment.
- No treatment availability claim.
- No university endorsement claim before approval.
- No token sale or investment-return language.
- No scraping or public exposure of scientists without consent.
- AI output is assistance only; human medical and scientific review is mandatory.
- Public-safe summaries and private evidence must be separated.